Balchem (BCPC) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales increased 4.3% year-over-year to $239.9 million, with record adjusted EBITDA of $64.4 million (up 7.6%) and net earnings up 16.4% to $33.8 million, driven by Human Nutrition and Health and Specialty Products, while Animal Nutrition and Health declined.

• Gross margin improved to 35.6% from 33.3%, with gross margin dollars up 11.5% year-over-year.

• Cash flow from operations was $51.3 million for the quarter and $129.7 million for the nine months, with free cash flow of $42.2 million and a cash balance of $73.7 million at quarter-end.

• Growth was led by Human Nutrition and Health and Specialty Products, supported by new product launches and innovation.

• The company maintains a strong margin profile, efficient cash flow conversion, and a solid balance sheet.

Financial highlights

• Q3 2024 net sales: $239.9 million (+4.3% YoY); adjusted EBITDA: $64.4 million (+7.6% YoY); adjusted net earnings: $36.9 million; adjusted EPS: $1.13; GAAP net earnings: $33.8 million; GAAP EPS: $1.03.

• Gross margin: $85.4 million (35.6% of sales), up from 33.3% last year.

• Operating income for Q3 2024: $48.0 million (+10.0% YoY); operating margin: 20.0%.

• Net debt ended at $153.3 million with a leverage ratio of 0.6x.

• Free cash flow conversion remains strong, with TTM free cash flow at 116% of non-GAAP net earnings.

Outlook and guidance

• Expect continued year-over-year growth in Q4 2024, supported by Human Nutrition and Health and Specialty Products, and sequential improvement in Animal Nutrition and Health.

• Gross margin rates expected to moderate as product mix normalizes and input cost deflation abates, but margins to remain strong historically.

• Effective tax rate projected to remain in the 22%-23% range for 2025.

• Focus remains on innovation, market penetration, and strategic M&A to drive long-term growth.

• Management expects sufficient cash flow to fund working capital and capital investments.